
## Jean-Luc Teillaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9308798/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 832-844.	5.6	564
2	Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects. Journal of Crohn's and Colitis, 2010, 4, 355-366.	1.3	284
3	Differential Modulation of Stimulatory and Inhibitory Fcγ Receptors on Human Monocytes by Th1 and Th2 Cytokines. Journal of Immunology, 2001, 166, 531-537.	0.8	215
4	Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood, 2010, 116, 926-934.	1.4	183
5	Structural Bases of Fcgamma Receptor Functions. Immunological Reviews, 1992, 125, 49-76.	6.0	137
6	Impact of Glycosylation on Effector Functions of Therapeutic IgG. Pharmaceuticals, 2010, 3, 146-157.	3.8	132
7	Regulated Expression and Inhibitory Function of FcÎ <sup>3</sup> RIIb in Human Monocytic Cells. Journal of Biological Chemistry, 2002, 277, 5082-5089.	3.4	120
8	Chronic lymphocytic leukaemia cells are efficiently killed by an anti D20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16. British Journal of Haematology, 2008, 140, 635-643.	2.5	115
9	FcγR: The key to optimize therapeutic antibodies?. Critical Reviews in Oncology/Hematology, 2007, 62, 26-33.	4.4	86
10	Novel Ganglioside Antigen Identified by B Cells in Human Medullary Breast Carcinomas: The Proof of Principle Concerning the Tumor-Infiltrating B Lymphocytes. Journal of Immunology, 2005, 175, 2278-2285.	0.8	82
11	Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene, 1999, 18, 551-557.	5.9	80
12	The identification of monoclonal class switch variants by sib selection and an ELISA assay. Journal of Immunological Methods, 1984, 74, 307-315.	1.4	79
13	The Fc Receptor for IgG Expressed in the Villus Endothelium of Human Placenta Is FcγRIIb2. Journal of Immunology, 2001, 166, 3882-3889.	0.8	77
14	Selection of a human anti-RhD monoclonal antibody for therapeutic use: Impact of IgG glycosylation on activating and inhibitory Fcl <sup>3</sup> R functions. Clinical Immunology, 2006, 118, 170-179.	3.2	77
15	FcÎ <sup>3</sup> RII expression in resting and activated B lymphocytes. European Journal of Immunology, 1989, 19, 1379-1385.	2.9	76
16	Single-Domain Antibody–Based and Linker-Free Bispecific Antibodies Targeting FcγRIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells. Molecular Cancer Therapeutics, 2013, 12, 1481-1491.	4.1	63
17	Llama singleâ€domain antibodies directed against nonconventional epitopes of tumorâ€associated carcinoembryonic antigen absent from nonspecific crossâ€reacting antigen. FEBS Journal, 2009, 276, 3881-3893.	4.7	58
18	Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer?. Frontiers in Immunology, 2017, 8, 830.	4.8	54

JEAN-LUC TEILLAUD

#	Article	IF	CITATIONS
19	Human Macrophages and Dendritic Cells Can Equally Present MART-1 Antigen to CD8+ T Cells after Phagocytosis of Gamma-Irradiated Melanoma Cells. PLoS ONE, 2012, 7, e40311.	2.5	50
20	Monoclonal antibodies as a tool for phylogenetic studies of major histocompatibility antigens and ? 2-microglobulin. Immunogenetics, 1982, 15, 377-384.	2.4	48
21	Molecular aspects of human Fc <sup>î</sup> ³R interactions with IgG: Functional and therapeutic consequences. Immunology Letters, 2006, 106, 111-118.	2.5	47
22	A human antiâ€Ð monoclonal antibody selected for enhanced FcγRIII engagement clears RhD <sup>+</sup> autologous red cells in human volunteers as efficiently as polyclonal antiâ€Ð antibodies. British Journal of Haematology, 2008, 141, 109-119.	2.5	47
23	Combining IR spectroscopy with fluorescence imaging in a single microscope: Biomedical applications using a synchrotron infrared source (invited). Review of Scientific Instruments, 2002, 73, 1357-1360.	1.3	42
24	Tertiary Lymphoid Structure-B Cells Narrow Regulatory T Cells Impact in Lung Cancer Patients. Frontiers in Immunology, 2021, 12, 626776.	4.8	39
25	A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms. PLoS ONE, 2011, 6, e26469.	2.5	38
26	A novel subset of NK cells expressing high levels of inhibitory FcÎ <sup>3</sup> RIIB modulating antibody-dependent function. Journal of Leukocyte Biology, 2008, 84, 1511-1520.	3.3	36
27	A New Set of Monoclonal Antibodies Against Human Fcl̂³RII (CD32) and Fcl̂³RIII (CD16): Characterization and Use in Various Assays. Hybridoma, 1997, 16, 519-528.	0.6	35
28	Tumor-Associated Tertiary Lymphoid Structures: From Basic and Clinical Knowledge to Therapeutic Manipulation. Frontiers in Immunology, 2021, 12, 698604.	4.8	35
29	Selective PCR Amplification of Functional Immunoglobulin Light Chain from Hybridoma Containing the Aberrant MOPC 21-Derived VIº by PNA-Mediated PCR Clamping. BioTechniques, 1999, 26, 818-822.	1.8	34
30	Generation of phagocytic MAK and MAC-DC for therapeutic use. Experimental Hematology, 1999, 27, 751-761.	0.4	28
31	In vivo induction of functional Fcl <sup>3</sup> RI (CD64) on neutrophils and modulation of blood cytokine mRNA levels in cancer patients treated with G-CSF (rMetHuG-CSF). British Journal of Haematology, 1998, 100, 550-556.	2.5	27
32	Detection and quantification of secreted soluble Fcl <sup>3</sup> RIIA in human sera by an enzyme-linked immunosorbent assay. Journal of Immunological Methods, 1993, 166, 1-10.	1.4	24
33	Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma. Immunology Letters, 1999, 65, 143-151.	2.5	24
34	Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer and Metastasis Reviews, 2011, 30, 111-124.	5.9	24
35	Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. Pathology and Oncology Research, 2005, 11, 92-97.	1.9	22
36	Recombinant interleukin 2-activated natural killer cells regulate IgG2a production. European Journal of Immunology, 1990, 20, 1781-1787.	2.9	21

JEAN-LUC TEILLAUD

#	Article	IF	CITATIONS
37	Activating and inhibitory FcÎ <sup>3</sup> receptors in immunotherapy: being the actor or being the target. Expert Review of Clinical Immunology, 2009, 5, 735-747.	3.0	17
38	Evaluation of circulating tumor necrosis factor-α in patients with gynecological malignancies. International Journal of Cancer, 1991, 48, 375-378.	5.1	15
39	Regulation of IgG production by suppressor FcγRII+ T hybridomas. European Journal of Immunology, 1990, 20, 55-61.	2.9	14
40	Involvement of FcR+ T cells and of IGG-BF in the control of myeloma cells. Molecular Immunology, 1990, 27, 1209-1217.	2.2	14
41	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of Fcl³RIIB. Journal of Immunology, 2008, 181, 5350-5359.	0.8	13
42	Possibilities of Interference with the Immune System of Tumor Bearers by Non-Lymphoid FcγRII Expressing Tumor Cells. Immunobiology, 1992, 185, 415-425.	1.9	11
43	Impact of Depleting Therapeutic Monoclonal Antibodies on the Host Adaptive Immunity: A Bonus or a Malus?. Frontiers in Immunology, 2017, 8, 950.	4.8	11
44	SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood, 2022, 139, 1160-1176.	1.4	11
45	Effect of zinc on human IgG1 and its FcÎ <sup>3</sup> R interactions. Immunology Letters, 2012, 143, 60-69.	2.5	10
46	FcγR expressed on T-cell hybrids: Specificity, behavior and relationship with Ia antigens. Cellular Immunology, 1981, 63, 349-361.	3.0	9
47	Molecular heterogeneity of murine IgG-BF. Molecular Immunology, 1986, 23, 1183-1191.	2.2	9
48	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	4.8	9
49	Analysis of DR-like molecules on a marmoset Epstein-Barr virus-induced cell line using a monomorphic anti-human HLA-DR monoclonal antibody. European Journal of Immunology, 1982, 12, 446-448.	2.9	8
50	Soluble Fcγ Receptor, FcγRIIa2, is Present in Two Forms in Human Serum and is Increased in Patients: With Stage C Chronic Lymphocytic Leukemia. Leukemia and Lymphoma, 1997, 26, 317-326.	1.3	8
51	Regulatory effects of IgG-BF on hybridoma B cells. Molecular characterization of variant cell lines. Molecular Immunology, 1988, 25, 1133-1142.	2.2	7
52	A tumor specific single chain antibody dependent gene expression system. Oncogene, 1999, 18, 559-564.	5.9	7
53	Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1561-1572.	4.2	6
54	Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use. British Journal of Haematology, 2001, 114, 671-680.	2.5	5

JEAN-LUC TEILLAUD

#	Article	IF	CITATIONS
55	Some cellular and molecular characteristics of high and low tumorigenicity variants of polyoma-virus transformed cells. Molecular Immunology, 1990, 27, 1219-1228.	2.2	4
56	High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function. Cancer Immunology, Immunotherapy, 2013, 62, 3-15.	4.2	4
57	Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?. Cancer Cell, 2022, 40, 240-243.	16.8	4
58	Le mot des coordinateurs. Medecine/Sciences, 2009, 25, 995-996.	0.2	3
59	Inhibitory IgG Receptor-Expressing Cells: The Must-Have Accessory for Anti-CD40 Immunomodulatory mAb Efficacy. Cancer Cell, 2016, 29, 771-773.	16.8	3
60	Involvement of human membrane-associated complement components in the rosette formation between Marmoset red blood cells and human leukocytes. Cellular Immunology, 1982, 66, 254-268.	3.0	2
61	Molecular characterization of two la-like antigens in marmoset. Immunogenetics, 1984, 19, 155-161.	2.4	2
62	In vitro inhibition of tumor B cell growth by IgG-BF-producing FcÎ <sup>3</sup> RII+T cell hybridoma and by immunoglobulin G-binding factors. Immunologic Research, 1992, 11, 296-304.	2.9	2
63	Epitope Mapping and Tight-Binding Inhibition with Monoclonal Antibodies Directed againstEscherichia coliClucosamine 6-phosphate Synthase. Archives of Biochemistry and Biophysics, 1995, 324, 391-400.	3.0	2
64	A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy. Oncolmmunology, 2020, 9, 1770565.	4.6	2
65	BMFPs, a versatile therapeutic tool for redirecting a preexisting Epstein-Barr virus antibody response toward defined target cells. Science Advances, 2022, 8, eabl4363.	10.3	2
66	Can NK Cells Play a Role in Anti-CD20 Immunotherapy for CLL Patients? Blood, 2007, 110, 3103-3103.	1.4	0
67	R603: A New Low Dose Efficient Anti-CD20 Immunotherapy for CLL Patients ?. Blood, 2008, 112, 4155-4155.	1.4	0